290 related articles for article (PubMed ID: 9486676)
21. Serum soluble interleukin-2 receptor (sIL-2R) level is associated with the outcome of patients with diffuse large B cell lymphoma treated with R-CHOP regimens.
Goto N; Tsurumi H; Goto H; Shimomura YI; Kasahara S; Hara T; Yasuda I; Shimizu M; Murakami N; Yoshikawa T; Fukuno K; Takahashi T; Kito Y; Takami T; Moriwaki H
Ann Hematol; 2012 May; 91(5):705-714. PubMed ID: 22183251
[TBL] [Abstract][Full Text] [Related]
22. Constitutive secretion of soluble interleukin-2 receptor by human T cell lymphoma xenografted into SCID mice. Correlation of tumor volume with concentration of tumor-derived soluble interleukin-2 receptor in body fluids of the host mice.
Wasik MA; Sioutos N; Tuttle M; Butmarc JR; Kaplan WD; Kadin ME
Am J Pathol; 1994 May; 144(5):1089-97. PubMed ID: 8178932
[TBL] [Abstract][Full Text] [Related]
23. A high sIL-2R/ferritin ratio is a useful marker for the diagnosis of lymphoma-associated hemophagocytic syndrome.
Tsuji T; Hirano T; Yamasaki H; Tsuji M; Tsuda H
Ann Hematol; 2014 May; 93(5):821-6. PubMed ID: 24705932
[TBL] [Abstract][Full Text] [Related]
24. Soluble interleukin-2 receptor in Sézary syndrome: its origin and clinical application.
Bernengo MG; Fierro MT; Novelli M; Lisa F; Appino A
Br J Dermatol; 1993 Feb; 128(2):124-9. PubMed ID: 8457444
[TBL] [Abstract][Full Text] [Related]
25. Increased CCL18 expression in patients with cutaneous T-cell lymphoma: association with disease severity and prognosis.
Miyagaki T; Sugaya M; Suga H; Ohmatsu H; Fujita H; Asano Y; Tada Y; Kadono T; Sato S
J Eur Acad Dermatol Venereol; 2013 Jan; 27(1):e60-7. PubMed ID: 22404649
[TBL] [Abstract][Full Text] [Related]
26. Serum amyloid A levels in the blood of patients with atopic dermatitis and cutaneous T-cell lymphoma.
Suzuki H; Sugaya M; Nakajima R; Oka T; Takahashi N; Nakao M; Miyagaki T; Asano Y; Sato S
J Dermatol; 2018 Dec; 45(12):1440-1443. PubMed ID: 30289574
[TBL] [Abstract][Full Text] [Related]
27. Serum level of a soluble receptor for interleukin-2 as a prognostic factor in patients with gastric cancer.
Saito H; Tsujitani S; Ikeguchi M; Maeta M; Kaibara N
Oncology; 1999 Apr; 56(3):253-8. PubMed ID: 10202282
[TBL] [Abstract][Full Text] [Related]
28. Biopsy of cervical lymph node.
Matsumoto F; Itoh S; Ohba S; Yokoi H; Furukawa M; Ikeda K
Auris Nasus Larynx; 2009 Feb; 36(1):71-4. PubMed ID: 18479855
[TBL] [Abstract][Full Text] [Related]
29. The clinical significance of serum soluble interleukin 2 receptor (sIL-2R) concentration in lung cancer.
Naumnik W; Chyczewska E
Folia Histochem Cytobiol; 2001; 39 Suppl 2():185-6. PubMed ID: 11820599
[TBL] [Abstract][Full Text] [Related]
30. Circulating interleukin-2 receptors are a group of multimeric proteins with immunoreactivity for interleukin-2 receptor alpha, beta, and gamma chains.
Dummer R; Posseckert G; Sugamura K; Grundmann H; Burg G
J Interferon Cytokine Res; 1996 Apr; 16(4):315-20. PubMed ID: 9162525
[TBL] [Abstract][Full Text] [Related]
31. Elevated serum-soluble interleukin-2 receptor levels in patients with anaplastic large cell lymphoma.
Janik JE; Morris JC; Pittaluga S; McDonald K; Raffeld M; Jaffe ES; Grant N; Gutierrez M; Waldmann TA; Wilson WH
Blood; 2004 Nov; 104(10):3355-7. PubMed ID: 15205267
[TBL] [Abstract][Full Text] [Related]
32. [Significance of soluble interleukin-2 receptor alpha chain in the management of patients with malignant lymphoma: a multi-center study].
Ohno H; Ishikawa T; Kitajima H; Nomura S; Suzuki T; Konishi H; Ohno Y; Onishi R; Konaka Y; Arima N; Doi S; Nasu K; Takahashi T; Tsudo M; Fukuhara S; Uchiyama T
Rinsho Ketsueki; 2002 Mar; 43(3):170-5. PubMed ID: 11979748
[TBL] [Abstract][Full Text] [Related]
33. High Level of Serum Soluble Interleukin-2 Receptor Is Associated With Poor Survival in Patients With First Relapsed or Refractory Peripheral T-Cell Lymphoma, Not Otherwise Specified: A Retrospective Study.
Morita-Fujita M; Katoh D; Shimomura Y; Ishikawa T
Clin Lymphoma Myeloma Leuk; 2019 Jul; 19(7):e337-e342. PubMed ID: 31053551
[TBL] [Abstract][Full Text] [Related]
34. Relationship between serum levels of soluble interleukin-2 receptor and various disease parameters in patients with squamous cell carcinoma of the esophagus.
Oka M; Hazama S; Takahashi M; Yamamoto K; Abe T; Yoshino S; Hayashi H; Tangoku A
Hepatogastroenterology; 1999; 46(28):2254-9. PubMed ID: 10521976
[TBL] [Abstract][Full Text] [Related]
35. High level of soluble interleukin-2 receptor in serum predicts treatment resistance and poor progression-free survival in multiple myeloma.
Wang L; Wang JH; Liu WJ; Wang WD; Wang H; Chen XQ; Geng QR; Lu Y; Xia ZJ
Ann Hematol; 2017 Dec; 96(12):2079-2088. PubMed ID: 28871325
[TBL] [Abstract][Full Text] [Related]
36. Serum levels of interleukin-18 (IL-18) and soluble interleukin-2 receptor (sIL-2R) in lung cancer.
Naumnik W; Chyczewska E; Kovalchuk O; Tałałaj J; Izycki T; Panek B
Rocz Akad Med Bialymst; 2004; 49():246-51. PubMed ID: 15631351
[TBL] [Abstract][Full Text] [Related]
37. Soluble interleukin-2 receptor in stage I-III melanoma.
Ottaiano A; Leonardi E; Simeone E; Ascierto PA; Scala S; Calemma R; Bryce J; Caracò C; Satriano RA; Gianfranco N; Franco R; Botti G; Castello G
Cytokine; 2006 Feb; 33(3):150-5. PubMed ID: 16517174
[TBL] [Abstract][Full Text] [Related]
38. Soluble interleukin-2 receptors (sIL-2R) in Hodgkin's disease: outcome and clinical implications.
Viviani S; Camerini E; Bonfante V; Santoro A; Balzarotti M; Fornier M; Devizzi L; Verderio P; Valagussa P; Bonadonna G
Br J Cancer; 1998 Mar; 77(6):992-7. PubMed ID: 9528846
[TBL] [Abstract][Full Text] [Related]
39. Serum adhesion molecules and interleukin-2 receptor as markers of tumour load and prognosis in advanced cutaneous melanoma.
Vuoristo MS; Laine S; Huhtala H; Parvinen LM; Hahka-Kemppinen M; Korpela M; Kumpulainen E; Kellokumpu-Lehtinen P
Eur J Cancer; 2001 Sep; 37(13):1629-34. PubMed ID: 11527688
[TBL] [Abstract][Full Text] [Related]
40. Prognostic value of the soluble interleukin-2 receptor level after patients with follicular lymphoma achieve a response to R-CHOP.
Umino K; Fujiwara SI; Ikeda T; Toda Y; Ito S; Mashima K; Minakata D; Nakano H; Yamasaki R; Kawasaki Y; Sugimoto M; Yamamoto C; Ashizawa M; Hatano K; Sato K; Oh I; Ohmine K; Muroi K; Kanda Y
Hematology; 2017 Oct; 22(9):521-526. PubMed ID: 28413914
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
